Semaglutide
Also known as: Semaglutide (GLP-1 agonist)
Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes management and chronic weight management. It mimics the incretin hormone GLP-1 to regulate appetite and glucose metabolism.
Pricing for Semaglutide
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
Average price
$9.31/mg
range $1.00–$44.70/mg
Sellers
62
from $0.00
45-day trend
+18.2%
vs 45-day avg $/mg
55 of 62 sellers have a current price· 44 stale listings hidden (not seen in 7 days)
Top Merit pick
🇺🇸 Peptide Partners99via Disclosed Labs · just now
$4.88/mg -47.6% vs avg$976
200mg
99.9% purity 14 COAs- 🇺🇸 Profound Aminos95
via Disclosed Labs · just now
$7.65/mg -17.8% vs avg$153
20mg
- 🇺🇸 Prime Peptides95
via Disclosed Labs · just now
$8.67/mg -6.9% vs avg$130
15mg
- 🇺🇸 Simple Peptide85
via Disclosed Labs · just now
$9.30/mg -0.1% vs avg$93.00
10mg
- 🇨🇳 Reta Peptide83
✓ verified at source · just now
$6.50/mg -30.2% vs avg$65.00
10mg
99.6% purity 7 COAs - 🇺🇸 Blank Peptides81
✓ verified at source · just now
$10.50/mg +12.8% vs avg$105
10mg
99.8% purity 2 COAs - 🇺🇸 OROS Research79
via Disclosed Labs · just now
$9.00/mg -3.3% vs avg$89.99
10mg
99.0% purity 1 COA - 🇺🇸 Texpeptide65
✓ verified at source · 1d ago
$7.50/mg -19.4% vs avg$150
20mg
no purity - 🇭🇰 Hkuppeptide50
✓ verified at source · just now
$1.00/mg -89.3% vs avg$10.00
10mg
no purity - 🇭🇰 zztai Peptide Ltd43
✓ verified at source · just now
$3.87/mg -58.5% vs avg$116
30mg
no purity - optimasupply.isUnscored
via Disclosed Labs · just now
$11.00/mg +18.2% vs avg$110
10mg
no purity
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
COAs for Semaglutide
153 third-party tests across 20 vendors. Each card links to the full report.
For
Semaglutide
by Peptide Partners· batch SPL-4149
For
Semaglutide
by Peptide Plugs· batch 125-01-SM
For
Semaglutide
by EZ Peptides· batch EZP-1P1005102026-03
For
Semaglutide
by EZ Peptides· batch EZP-1P1005102026-03
For
Semaglutide
by Pepsgpt· batch P-2885342-P
For
Semaglutide
by Prime Peptides· batch 3022026SM
For
Semaglutide
by Prime Peptides· batch 3142026SM
For
Semaglutide
by Prime Peptides· batch 2242026SM
For
ION-1S
by Ion Peptide· batch ION1S20-04172026
For
Semaglutide
by OROS Research· batch OR-LPGLPS10-426-B3
For
Semaglutide
by Prime Peptides· batch 3272026SM
For
Semaglutide
by Prime Peptides· batch 3222026SX
For
Semaglutide
by Blank Peptides· batch 665394
For
Semaglutide
by Prime Peptides· batch 2182026SM
For
Semaglutide
by Prime Peptides· batch 2122026SM
For
Semaglutide
by Orbitrex Peptides· batch 1G200426
For
Semaglutide
by Qihang Peptide· batch 3
For
Semaglutide
by Reta One Labs· batch SM100326
For
Semaglutide
by Reta One Labs· batch SM200326
For
Semaglutide
by EZ Peptides· batch EZP-1P0502152026-01
For
Semaglutide
by EZ Peptides· batch EZP-1P0502152026-01
For
Semaglutide
by Reta One Labs· batch SM100326
For
Semaglutide
by Reta One Labs· batch SM200326
For
Semaglutide
by Prime Peptides· batch 1052026SM
23 citations indexed for Semaglutide
rct · 2027
SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer
SHAPE-ENDO is a single-center, open-label, pilot randomized clinical trial conducted at Hospital Universitari de Bellvitge in Barcelona, Spain.
cohort · 2026
Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials
Background Obesity is a chronic, progressive disease affecting over 1 billion adults worldwide, linked to serious comorbidities, including diabetes, hypertension, and cardiovascular disease and associated with increased mortality. Achieving clinically meaningful weight loss is critical to reducing cardiometabolic risk.
Study · 2026
Effect of Semaglutide on Measured vs Estimated Glomerular Filtration Rate
Background and hypothesis Semaglutide is a glucagon-like peptide-1 receptor agonist widely used for its glucose-lowering effects in people with type 2 diabetes (T2D), as well as its cardiovascular and kidney-protective properties.
rct · 2026
Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial
Importance Consistent results from preclinical and clinical studies indicate that activation of glucagon-like peptide-1 receptors (GLP-1 Rs) affects reward processes; however, to our knowledge, no study has previously evaluated whether a GLP-1 R agonist (GLP-1 RA) affects motivated behavior in individuals with major de…
Study · 2026
High-yield recombinant production of the semaglutide main chain P29 intermediate using SNAC-tagged enterokinase-cleavable fusion peptides
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insufficient insulin secretion or impaired cellular response to insulin, resulting in increased blood sugar levels and persistent hyperglycemia.
review · 2026
The risk of retinal vascular events in patients using semaglutide: a scoping review
Background This scoping review aims to explore existing clinical trials on the association between semaglutide use and the occurrence of retinal vascular events to detect any potential safety concern.